Loading...
Market
Will Lundbeck's acquisition of Longboard Pharmaceuticals receive regulatory approval by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Regulatory announcements from relevant authorities such as the European Commission or U.S. FTC
Story
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 10:41 AM
Lundbeck, a Danish pharmaceutical company, has announced its acquisition of Longboard Pharmaceuticals for $60 per share in cash, valuing the deal at approximately $2.6 billion. The acquisition, which has been unanimously approved by the boards of both companies, is expected to close in the fourth quarter of 2024 pending regulatory approvals. This strategic deal aims to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments. The transaction, representing a 77% premium to VWAP, will be funded through existing cash resources and bank financing, totaling DKK17B. Centerview LLC acted as the advisor for the deal.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
On time (by Q4 2024) • 25%
Delayed to Q1 2025 • 25%
Delayed to Q2 2025 or later • 25%
Deal Cancelled • 25%
Lundbeck's stock rises over 5% • 25%
Lundbeck's stock falls over 5% • 25%
Longboard's stock remains stable • 25%
Other • 25%
Antitrust Concerns • 25%
Financial Discrepancies • 25%
Intellectual Property Issues • 25%
Other • 25%
Positive • 25%
Neutral • 25%
Negative • 25%
Mixed • 25%
Increase > 10% • 25%
Increase 0-10% • 25%
Decrease 0-10% • 25%
Decrease > 10% • 25%